We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+11.61%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$1.17B
AUM Growth
+$164M
Cap. Flow
+$76.2M
Cap. Flow %
6.49%
Top 10 Hldgs %
32.39%
Holding
149
New
25
Increased
54
Reduced
51
Closed
11

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$11.9M
2
CI icon
Cigna
CI
+$11.9M
3
PRAH
PRA Health Sciences, Inc.
PRAH
+$11.1M
4
VTRS icon
Viatris
VTRS
+$10.5M
5
CELG
Celgene Corp
CELG
+$8.17M

Top Sells

Rank Stock Value
1
INCY icon
Incyte
INCY
+$12M
2
UNH icon
UnitedHealth
UNH
+$11M
3
ALGN icon
Align Technology
ALGN
+$9.05M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$8.45M
5
IART icon
Integra LifeSciences
IART
+$8.23M

Sector Composition

Rank Sector Weight
1 Healthcare 93.53%
2 Industrials 0.76%
3 Technology 0.15%
4 Financials 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IDXX icon
101
Idexx Laboratories
IDXX
$44.6B
$1.53M 0.13%
+7,000
New +$1.44M
MASI
102
DELISTED
Masimo
MASI
$1.45M 0.12%
14,800
-2,200
-13% -$209K
CLLS
103
Cellectis
CLLS
$262M
$1.43M 0.12%
50,600
-1,500
-3% -$44.7K
OXFD
104
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$1.43M 0.12%
+110,661
New +$1.49M
ITCI
105
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$1.41M 0.12%
79,900
-11,100
-12% -$225K
DVAX
106
DELISTED
Dynavax Technologies
DVAX
$1.4M 0.12%
91,800
-2,700
-3% -$46.7K
ARNA
107
DELISTED
Arena Pharmaceuticals Inc
ARNA
$1.37M 0.12%
+31,417
New +$1.35M
ALKS icon
108
Alkermes
ALKS
$8.71B
$1.34M 0.11%
32,650
-18,250
-36% -$831K
STIM icon
109
Neuronetics
STIM
$132M
$1.32M 0.11%
+50,000
New +$1.36M
AET
110
DELISTED
Aetna Inc
AET
$1.3M 0.11%
7,100
-1,900
-21% -$339K
MRTX
111
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$1.26M 0.11%
+25,500
New +$963K
SYNH
112
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
$1.25M 0.11%
+26,656
New +$1.1M
AMRX icon
113
Amneal Pharmaceuticals
AMRX
$5.63B
$1.23M 0.1%
+75,000
New +$1.32M
CSLT
114
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$1.22M 0.1%
+287,340
New +$1.08M
FMI
115
DELISTED
Foundation Medicine, Inc.
FMI
$1.14M 0.1%
+8,357
New +$759K
TSRO
116
DELISTED
TESARO, Inc.
TSRO
$1.12M 0.1%
25,250
-119,552
-83% -$5.81M
INGN icon
117
Inogen
INGN
$171M
$1.12M 0.1%
+6,011
New +$1M
COTV
118
DELISTED
Cotiviti Holdings, Inc.
COTV
$1.09M 0.09%
24,774
+3,066
+14% +$111K
PFE icon
119
Pfizer
PFE
$142B
$1.06M 0.09%
30,777
– –
GWPH
120
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$1M 0.09%
7,179
+2,304
+47% +$327K
ENDP
121
DELISTED
Endo International plc
ENDP
$934K 0.08%
99,092
+36,892
+59% +$248K
CAH icon
122
Cardinal Health
CAH
$53.1B
$879K 0.07%
18,000
-2,000
-10% -$113K
VEEV icon
123
Veeva Systems
VEEV
$32.3B
$791K 0.07%
+10,296
New +$783K
CLVS
124
DELISTED
Clovis Oncology, Inc.
CLVS
$784K 0.07%
17,250
-500
-3% -$24.3K
QURE icon
125
uniQure
QURE
$2.77B
$764K 0.07%
+20,200
New +$647K
2 3 4
5
6

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q2 2018 Portfolio in Review

As of Q2 2018, Bellevue Group held 149 positions worth $1.17B, up 16% from $1.01B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Bellevue Group deployed $76.2M of net new capital in Q2 2018, opening 25 new positions and adding to 54 existing holdings. Its largest new stake was PRA Health Sciences, Inc.: 129,400 shares worth $12.1M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier, followed by Industrials and Technology.

On the sell side, the largest reduction was Incyte, an estimated $12M trimmed.

  • Bellevue Group's largest Q2 2018 buy was PRA Health Sciences, Inc.: 129,400 shares worth $12.1M.
  • Bellevue Group added most to Bristol-Myers Squibb in Q2 2018, an estimated $11.9M increase.
  • Bellevue Group's biggest Q2 2018 reduction was Incyte, cutting an estimated $12M.
  • Bellevue Group fully exited Perrigo in Q2 2018, selling an estimated $2.75M.
  • Bellevue Group's ten largest holdings make up 32% of its $1.17B portfolio in Q2 2018.
  • Bellevue Group opened 25 new positions and closed 11 in Q2 2018.
  • Bellevue Group's portfolio value rose 16% quarter-over-quarter to $1.17B.

Based on Bellevue Group's 13F filing for Q2 2018, filed 7 Aug 2018.